TDI-01 is under clinical development by Graviton Bioscience and currently in Phase I for Pulmonary Fibrosis. According to GlobalData, Phase I drugs for Pulmonary Fibrosis have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how TDI-01’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

TDI-01 overview

TDI-01 is under development for the treatment of non-alcoholic steatohepatitis (NASH), coronavirus disease 2019 (COVID-19) pneumonia, idiopathic pulmonary fibrosis, pulmonary fibrosis and pneumoconiosis. It acts by targeting Rho/Rho associated coiled-coil containing protein kinase 2 (ROCK2). It is administered through oral route.

Graviton Bioscience overview

Graviton Bioscience is a drug development company. The company is headquartered in New York City, New York, the US.

For a complete picture of TDI-01’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.